Conditions: Moderate to Severe Plaque-type Psoriasis
Keywords: Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 177
Healthy volunteers: no

Brief summary:
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.

Detailed description:

Arms:
arm 1: Drug arm 2: Drug arm 3: None

Interventions: intervention 1: secukinumab 150 mg intervention 2: secukinumab 300 mg intervention 3: placebo
Intervention descriptions: intervention 1: After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period intervention 2: After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period intervention 3: Subjects who were on placebo at Week 52 cannot continue in the extension treatment period

Protocol document: